Parkman Healthcare Partners LLC Acquires 15,318 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Parkman Healthcare Partners LLC boosted its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 924,140 shares of the company’s stock after acquiring an additional 15,318 shares during the period. Day One Biopharmaceuticals accounts for 1.6% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 21st largest position. Parkman Healthcare Partners LLC owned 0.92% of Day One Biopharmaceuticals worth $12,873,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in Day One Biopharmaceuticals in the third quarter valued at about $825,000. First Turn Management LLC bought a new position in Day One Biopharmaceuticals in the third quarter valued at about $13,204,000. Algert Global LLC boosted its holdings in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock valued at $996,000 after acquiring an additional 50,990 shares during the last quarter. Vestal Point Capital LP grew its position in shares of Day One Biopharmaceuticals by 100.0% during the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,250,000 shares during the period. Finally, Braidwell LP lifted its holdings in shares of Day One Biopharmaceuticals by 60.5% during the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after purchasing an additional 1,837,949 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the transaction, the insider now owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. The trade was a 0.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 51,745 shares of company stock worth $775,867 in the last ninety days. 8.40% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

Shares of DAWN opened at $13.59 on Wednesday. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.51 and a 1-year high of $18.07. The firm has a fifty day moving average price of $14.31 and a 200 day moving average price of $14.11. The stock has a market cap of $1.37 billion, a PE ratio of -13.19 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the business earned ($0.54) EPS. As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.